3i Diagnostics Inc is an innovative company based in Germantown, MD, specializing in the development of novel diagnostics for identifying pathogens directly from blood without the need for culturing. Their Biospectrix platform technology is designed to be accessible worldwide as a point-of-care device, offering exponential cost reduction and easy miniaturization due to its materials and lack of refrigeration requirements.
Recently, the CEO of 3i Diagnostics, James Janicki, was invited to present at the Longitude Prize Workshop in Boston, where he showcased the technology they have been developing and its feasibility in addressing the Antimicrobial Crisis. The Longitude Prize, a 10 million prize fund, aims to incentivize the development of an affordable, accurate, and fast point-of-care test for bacterial infections, aligning with 3i Diagnostics' mission to provide health professionals worldwide with the ability to administer the right antibiotics at the right time.
Generated from the website